3,734 reports of this reaction
3.8% of all CARBIDOPA AND LEVODOPA reports
#3 most reported adverse reaction
HALLUCINATION is the #3 most commonly reported adverse reaction for CARBIDOPA AND LEVODOPA, manufactured by Amneal Pharmaceuticals LLC. There are 3,734 FDA adverse event reports linking CARBIDOPA AND LEVODOPA to HALLUCINATION. This represents approximately 3.8% of all 97,592 adverse event reports for this drug.
Patients taking CARBIDOPA AND LEVODOPA who experience hallucination should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HALLUCINATION is moderately reported among CARBIDOPA AND LEVODOPA users, representing a notable but not dominant share of adverse events.
In addition to hallucination, the following adverse reactions have been reported for CARBIDOPA AND LEVODOPA:
The following drugs have also been linked to hallucination in FDA adverse event reports:
HALLUCINATION has been reported as an adverse event in 3,734 FDA reports for CARBIDOPA AND LEVODOPA. This does not prove causation, but indicates an association observed in post-market surveillance data.
HALLUCINATION accounts for approximately 3.8% of all adverse event reports for CARBIDOPA AND LEVODOPA, making it one of the most commonly reported side effect.
If you experience hallucination while taking CARBIDOPA AND LEVODOPA, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.